Definium Therapeutics Inc. (DFTX) exhibits 41.0% gross margins and -32.2% return on invested capital within Health Care (Medicinal Chemicals and Botanical Products), balanced against a 24.0x enterprise multiple and 7.2% implied options volatility.
Sustained 41.0% gross profitability converts into -11.6% operating margin and -32.2% ROIC, outpacing sector cost of capital.
ROIC: -32.2% // GM: 41.0%YoY revenue trajectory of +5.5% paired with -3.84% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +5.5% // FCF YLD: -3.84%Altman Z-Score of 26.00 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 26.00 // F-SCORE: 5/9Trading at 24.0x trailing P/E (33.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±7.2% implied move with a 0.92 put/call ratio around $37.00 max pain.
IMPL MOVE: ±7.2% // P/C: 0.92Elevated industry capital intensity and customer concentration in Medicinal Chemicals and Botanical Products require continuous execution to defend -12.9% net margins.
NET MARGIN: -12.9% // D/E: 0.12x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for DFTX & activate live FRED threshold breach alerts.